Videos

“[These favorable findings just speak] to the complexity of the health index for these patients,” says Neal D. Shore, MD, FACS.

“It's the first time that any gene expression test has been analyzed in a randomized trial, even if it's post-hoc, in intermediate-risk patients,” says Daniel E. Spratt, MD.

“There's no question that many patients [undergoing transurethral BPH surgery] can be done as a same-day ambulatory procedure. But you need to look at the criteria as to who you're going to keep and who you're not going to keep,” says Michael A. Palese, MD.

Kelly L. Stratton, MD, FACS, highlights 5 pivotal prostate cancer studies from the 2022 ASCO Genitourinary Cancers Symposium.

Christine Ibilibor, MD, discusses 6 noteworthy abstracts from the 2022 Genitourinary Cancers Symposium.

“I think research is a very important tool,” says Padraic O’Malley, MD, MSc, FRCSC.

"There have been few therapies that have so galvanized management of a urologic condition as what we've witnessed over the past decade regarding the use of onabotulinumtoxinA (Botox) for bladder dysfunction," says Melissa R. Kaufman, MD, PhD, FACS.

First-line treatment options available for patients with high-risk non-muscle invasive bladder cancer and variables that affect treatment decisions.

Frontline treatment approaches recommended by urologists and medical oncologists for patients with non-metastatic muscle-invasive bladder cancer.

“Your vision is better, your instruments are better, and so we can do an excellent cancer operation while maintaining really good rates of continence and potency recovery,” says David Lee, MD.

“I think it's important for urologists and physicians to have an open mind in regard to complementary approaches to the treatment of BPH-related LUTS in men,” says J. Curtis Nickel, MD, FRCSC.

“We definitely don't have a clear standard,” says Shawn Dason, MD, FRCSC.

“These findings are an internal validation that the disparities we're seeing are real,” says Padraic O’Malley, MD, MSc, FRCSC.

“Goal setting for the patient is important,” says Omar El Shahawy, MD, MPH, PhD.

“We call this a ‘disruptive innovation,’” says Leonard S. Marks, MD.

“The most notable finding is that more than half of all adult US women experience urinary incontinence,” says Heidi Wendell Brown, MD, MAS, FACOG.

“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.

"A major innovation impacting urology and oncology is the therapeutic advances based on genetic information," says Veda N. Giri, MD.

An overview of treatment guidelines available to support urologists and medical oncologists who manage patients with bladder cancer.

Types of educational resources available to support patients with bladder cancer as recommended by urologists and medical oncologists.

“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.

We've never had an imaging agent like this before,” says Leonard S. Marks, MD.

Karim Chamie, MD, describes what treatments might be on the horizon for muscle invasive bladder cancer and provides some clinical pearls to manage patients with MIBC.

A bladder cancer expert several ongoing clinical trials in the neoadjuvant and adjuvant setting.

An oncologist reviews the use of nivolumab in the adjuvant setting for treating high-risk muscle invasive bladder cancer and experience from his practice.

Dr. Karim Chamie details the available primary and adjuvant treatments for muscle invasive bladder cancer.

Karim Chamie, MD, presents the case of a 75-year-old woman with high-risk muscle invasive bladder cancer.

“If you're looking at our results, in terms of the percent of authors who are female, the percent of first authors are female, or last authors who are female, we've seen growth in all 3 categories over the last 18 years,” said Megan Prunty, MD.

Closing out his discussion on saw palmetto extracts in benign prostatic hyperplasia and lower urinary tract symptoms, Bilal Chughtai, MD, shares practical advice for physicians.

A brief review of the safety profile associated with use of saw palmetto extracts in benign prostatic hyperplasia and lower urinary tract symptoms.